Profile data is unavailable for this security.
About the company
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
- Revenue in USD (TTM)12.68m
- Net income in USD-232.03m
- Incorporated2015
- Employees55.00
- LocationImmunome Inc18702 N. CREEK PARKWAY, SUITE 100BOTHELL 98011United StatesUSA
- Phone+1 (610) 321-3700
- Fax+1 (302) 655-5049
- Websitehttps://immunome.com/
More ▼
Mergers & acquisitions
| Acquired company | IMNM:NAQ since announced | Transaction value |
|---|---|---|
| Atreca Inc-Antibody-Related Assets and Materials | 45.37% | 12.50m |
| Morphimmune Inc | 130.96% | 15.20m |
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | 86.73m | -260.15m | 781.69m | 344.00 | -- | 1.99 | -- | 9.01 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Disc Medicine Inc | 0.00 | -80.60m | 800.23m | 74.00 | -- | 2.36 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 803.51m | 116.00 | -- | 2.15 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 810.26m | 50.00 | -- | 2.58 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 819.51m | 140.00 | -- | 3.10 | -- | 22.01 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 821.42m | 180.00 | -- | 3.11 | -- | 6.60 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 826.65m | 300.00 | -- | 2.31 | -- | 4.32 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Immunome Inc | 12.68m | -232.03m | 827.57m | 55.00 | -- | 2.88 | -- | 65.25 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 837.25m | 168.00 | -- | -- | -- | 20.64 | -3.36 | -3.36 | 0.5934 | -- | -- | -- | -- | 241,428.60 | -- | -47.40 | -- | -54.18 | -- | -- | -506.16 | -- | -- | -- | -- | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 839.13m | 110.00 | -- | 5.33 | -- | 106.96 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Evolus Inc | 219.70m | -60.00m | 840.23m | 279.00 | -- | 45.31 | -- | 3.82 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Humacyte Inc | 0.00 | -105.70m | 840.74m | 183.00 | -- | 32.15 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Nuvation Bio Inc | 0.00 | -68.87m | 860.15m | 159.00 | -- | 1.28 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Viridian Therapeutics Inc | 288.00k | -218.13m | 863.52m | 96.00 | -- | 2.25 | -- | 2,998.33 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
Data as of May 21 2024. Currency figures normalised to Immunome Inc's reporting currency: US Dollar USD
40.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Mar 2024 | 4.89m | 8.19% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 4.53m | 7.60% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 3.88m | 6.50% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.23m | 3.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.98m | 3.31% |
| Point72 Asset Management LPas of 31 Mar 2024 | 1.65m | 2.76% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 1.52m | 2.54% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.51m | 2.54% |
| Woodline Partners LPas of 31 Mar 2024 | 1.32m | 2.21% |
| Avidity Partners Management LPas of 31 Mar 2024 | 873.89k | 1.46% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
